Evidence map›Paper›PMID 25691936›Full record

ArticleIranian journal of basic medical sciences2014

Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine.

Fariba Sadeghi Fazel, Mahnaz Haddadi, Alireza Khoshnevisan, Samad Muhammadnejad, Ahad Muhammadnejad, Zohreh Mazaheri, Motahareh Arjomandnejad, Reza Shirkoohi, Mohammad-Ali Oghabian, Narjes Sherkat-Khameneh and 2 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of basic medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Fariba Sadeghi FazelHealth Management Department, Quality Assurance Deputy, Razi Vaccine & Serum Research Institute, Karaj, Iran.
Mahnaz HaddadiCancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Alireza KhoshnevisanDepartment of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Samad MuhammadnejadResearch Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
Ahad MuhammadnejadCancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Zohreh MazaheriAnatomy Department, School of Medicine, Tarbiat Modares University, Tehran, Iran.
Motahareh ArjomandnejadOmid Institute for Advance Biomodels, Incubation Center for Medical Devices, Tehran University of Medical Sciences, Tehran, Iran.
Reza ShirkoohiCancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad-Ali OghabianResearch Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
Narjes Sherkat-KhamenehResearch Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
Saeid AmanpourCancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Monireh KazemimaneshVirology Department, Pasteur Institute of Iran, Tehran, Iran.
Tehran University of Medical Sciences · IRPasteur Institute of Iran · IRShariati Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesP In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. MATERIALS AND

methodsSingle cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay.

resultsThere was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods.

conclusionThis work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.

Indexed as

GlioblastomamultiformIn vitro chemosensitivity and resistance assayPersonalized medicinePrimary explant techniqueStereotactic biopsy

Identifiers

PMID25691936
PMCPMC4328103
OpenAlexW1660704515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.